Submission Deadline 11/10/2026
Fiscal Capacity $50,135,013
HHS-NIH11 Grant — Key Facts
Opportunity Number RFA-CA-27-002
Agency HHS-NIH11
Application Deadline 11/10/2026
Award Amount $50,135,013
Status Posted
Sector Health
Cost Sharing Not Required

Fiscal Parameters & Taxonomy

Authority HHS-NIH11
Status Posted

Who Can Apply

Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification) City or township governments Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses County governments Public housing authorities/Indian housing authorities Independent school districts Special district governments State governments

Eligibility Intelligence

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Program Description

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

CFDA Programs

93.394 Cancer Detection and Diagnosis Research

Agency Contact

National Cancer Institute (NCI) NCI-IMAT@nih.gov

✉ NCI-IMAT@nih.gov

📞 301-402-2541

Related Intelligence Guides

In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.

GrantMetric Intelligence Systems — Independent federal grant intelligence platform. Not affiliated with Grants.gov, the U.S. Department of Health & Human Services, or any government agency. Grant data is sourced from the Grants.gov API for informational purposes only; always verify opportunity details directly with the funding agency before applying. Some links on this site are affiliate links — we may earn a commission at no additional cost to you. Full Disclaimer  ·  Last Reviewed: May 2026  ·  Data Methodology